Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis

Digestive Diseases and Sciences

Volumn 55, Issue 5, 2010, Pages 1286-1295

  Nie, Qing He ^a   Zhu, Chuan Long ^b   Zhang, Ya Fei ^c   Yang, Jie ^a   Zhang, Jiu Cong ^a   Gao, Ren Tao ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antisense oligonucleotide; Gene therapy; Liver fibrosis; Model rat; Tissue inhibitors of metalloproteinases

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ANTISENSE OLIGONUCLEOTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; HUMAN SERUM ALBUMIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; COLLAGEN; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DISEASE COURSE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HYDRODYNAMICS BASED TRANSFECTION; IN VITRO STUDY; LIVER FIBROSIS; LIVER FUNCTION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL; WESTERN BLOTTING; ANIMAL; GENE THERAPY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; LIVER CIRRHOSIS; METABOLISM; METHODOLOGY; NONPARAMETRIC TEST; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; LIVER CIRRHOSIS; OLIGONUCLEOTIDES, ANTISENSE; RANDOM ALLOCATION; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM ALBUMIN; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77953648271     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0858-5     Document Type: Article

References (30)

1. Giannelli G, Quaranta V, Antonaci S. Tissue remodelling in liver diseases. Histol Histopathol. 2003;18:1267-1274.
2. Hsu YC, Chiu YT, Cheng CC, et al. Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J Gastroenterol Hepatol. 2007;22:99-111. doi:10.1111/j.1440-1746.2006.04361.x. (Pubitemid 44953424)
3. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol. 2005;3:95-107. doi:10.1016/S1542-3565(04)00445-8. (Pubitemid 40220303)
4. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol. 2003;38:S38-S53. doi:10.1016/S0168-8278(02)00429-4. (Pubitemid 39658635)
5. Hemmann S, Graf J, Roderfeld M, et al. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 2007;46:955-975. doi:10.1016/j.jhep.2007.02.003. (Pubitemid 46529049)
6. Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 2004;99:271-279. doi:10.1111/j.1572-0241.2004.04055.x. (Pubitemid 38279869)
7. Wei S, Chen Y, Chung L, et al. Protein engineering of the tissue inhibitor of metalloproteinase 1(TIMP-1) inhibitory domain. J Biol Chem. 2003;278:9831-9834. doi:10.1074/jbc.M211793200. (Pubitemid 36800485)
8. Bedossa P, Paradis V. Liver extracellular matrix in health and disease. J Pathol. 2003;200:504-515. doi:10.1002/path.1397. (Pubitemid 36818251)
9. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis. 2001;21:427-436. doi:10.1055/s-2001-17557. (Pubitemid 32923770)
10. Nie QH, Cheng YQ, Xie YM, et al. Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis. World J Gastroenterol. 2001;7:363-369.
11. Itoh Y, Itoh Y, Takamura A, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 2001;20:4782-4793. doi:10.1093/emboj/20.17.4782. (Pubitemid 32848631)
12. Santoro M, Battaglia C, Zhang L, et al. Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. Exp Cell Res. 1994;213:398-403. doi:10.1006/excr.1994.1215. (Pubitemid 24259485)
13. Wang BE. Animals with liver fibrosis induced by albumin immunization. Zhonghua Yixue Zazhi. 1989;69:503-505.
14. Nie QH, Zhang YF, Xie YM, et al. Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models. World J Gastroenterol. 2006;12:3044-3049.
15. Wang QC, Feng ZH, Zhou YX, et al. Induction of hepatitis C virus-specific cytotoxic T and B cell responses by dendritic cells expressing a modified antigen targeting receptor. World J Gastroenterol. 2005;11:557-560.
16. Sakaida I, Hironaka K, Uchida K, et al. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology. 1998;28:1247-1252. doi:10.1002/hep.510280512. (Pubitemid 28493834)
17. Walsh KM, Timms P, Campbell S, et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C. Dig Dis Sci. 1999;44:624-630. doi:10.1023/A:1026630129025.
18. Kobayashi H, Li ZX, Yamataka A, et al. Clinical evaluation of serum levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases as predictors of progressive fibrosis in post-operative biliary atresia patients. J Pediatr Surg. 2002;37:1030-1033. doi:10.1053/jpsu.2002.33836. (Pubitemid 34742839)
19. Von Weizsacker F. Management of chronic hepatitis B. Praxis (Bern 1994). 2005;94:649-652.
20. Wong W, Terrault N. Update on chronic hepatitis C. Clin Gastroenterol Hepatol. 2005;3:507-520. doi:10.1016/S1542-3565(05)00247-8. (Pubitemid 40834227)
21. Ball HA, Van Scott MR, Robinson CB. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin Rev Allergy Immunol. 2004;27:207-217. doi:10.1385/CRIAI:27:3: 207. (Pubitemid 40216081)
22. Cheng K, Mahato RI. Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst. 2007;24:93-146.
23. Crooke ST. Antisense strategies. Curr Mol Med. 2004;4:465-487. doi:10.2174/1566524043360375. (Pubitemid 38961192)
24. Ueberham E, Löw R, Ueberham U, et al. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology. 2003;37:1067-1078. doi:10.1053/jhep.2003.50196. (Pubitemid 36538683)
25. Hu YB, Li DG, Lu HM. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J Gene Med. 2007;9:217-229. doi:10.1002/jgm.1009. (Pubitemid 46523539)
26. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med. 2004;351:1772-1777. doi:10.1056/NEJMra045004. (Pubitemid 39383212)
27. Cordeiro MF, Mead A, Ali RR, et al. Novel antisense oligonucleotides targeting TGF-βinhibit in vivo scarring and improve surgical outcome. Gene Ther. 2003;10:59-71. doi:10.1038/sj.gt.3301865. (Pubitemid 36175827)
28. Mccaffrey AP, Meuse L, Karimi M, et al. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology. 2003;38:503-508. doi:10.1053/jhep.2003.50330. (Pubitemid 36919872)
29. Rayburn ER, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today. 2008;13(11-12):513- 521.
30. Mourich DV, Marshall NB. Antisense approaches to immune modulation for transplant and autoimmune diseases. Curr Opin Pharmacol. 2005;5:508-512. doi:10.1016/j.coph.2005.04.018. (Pubitemid 41258569)